Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Genedrive PLC (GDR.L) Excellent performance data for Genedrive® HCV test
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive PLC (GDR.L) PHE National Framework Agreement
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
Genedrive PLC (GDR.L) Half Year Report
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive PLC (GDR.L) Distribution agreement
Genedrive enters distribution agreement with Mountain Horse Solutions
Genedrive PLC (GDR.L) Antibiotic Induced Hearing Loss update
New clinical guidance in the UK supports assay
Genedrive PLC (GDR.L) First US shipments of Genedrive® 96 SARS-CoV-2 Kit
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.
Genedrive PLC (GDR.L) Distribution agreement with Beckman Coulter
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
Genedrive PLC (GDR.L) 96 SARS CoV-2 Kit able to detect all published virus strains
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released
Genedrive PLC (GDR.L) Notification of intent to distribute in the USA
Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
Genedrive PLC (GDR.L) HCV ID Kit demonstrates high clinical accuracy in India study
Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Realtime HCV test